June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Fabarius, A.

S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3(S1):742-743, June 2019.

Author:
Fabbiano, F.

S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3(S1):392-393, June 2019.

S1617 A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY

Chiaretti, S.; Bassan, R.; Vitale, A.; More

HemaSphere. 3(S1):746, June 2019.

Author:
Fabbri, A.

PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI

Mazza, R.; Spina, M.; Califano, C.; More

HemaSphere. 3(S1):563-564, June 2019.

Author:
Fabbri, M.

PF510 A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA

Vegliante, M.C.; De Summa, S.; Fabbri, M.; More

HemaSphere. 3(S1):208, June 2019.

Author:
Fabian, F.

PS943 SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE

Dourthe, M.E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3(S1):425, June 2019.

PS1168 CHROMATIN TOPOLOGY AND THREE-DIMENSIONAL ORGANIZATION OF CHROMOSOME TERRITORIES 9 AND 22 IN CD34+ BONE MARROW CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS

Fabian-Morales, E.; Torres, Y.L. Rodriguez; Escamilla, D.G. Vallejo; More

HemaSphere. 3(S1):531, June 2019.

Author:
Fabienne, S.
Author:
Fabre, M.
Author:
Fabri, O.

PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Niemeyer, C.M.; Flotho, C.; Lipka, D.B.; More

HemaSphere. 3(S1):292, June 2019.

Author:
Fabris, F.
Author:
Fabris, S.
Author:
Fabro, V. Del
Author:
Faça, V.M.

PS990 INTEGRATED ANALYSIS OF NTAL RELATED GENES IMPROVES OUTCOMES PREDICTION OF EUROPEAN LEUKEMIANET 2008 RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA

Pereira-Martins, D.A.; Thome, C.H.; Aguiar, G.F.; More

HemaSphere. 3(S1):444-445, June 2019.

Author:
Facchetti, F.

PF529 PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS

Crucitti, L.; Rusconi, C.; Re, A.; More

HemaSphere. 3(S1):217, June 2019.

Author:
Facchin, G.

PS1276 EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS

Facchin, G.; Candoni, A.; Busca, A.; More

HemaSphere. 3(S1):584, June 2019.

Author:
Facchini, E.
Author:
Facco, M.

PS1145 TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL)

Pagano, M.A.; Tibaldi, E.; Brunati, A.M.; More

HemaSphere. 3(S1):518-519, June 2019.

Author:
Facon, T.

S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3(S1):24-25, June 2019.

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3(S1):248-249, June 2019.

PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3(S1):252, June 2019.

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3(S1):255, June 2019.

PF612 ONCE-WEEKLY (70 MG/M2) VERSUS TWICE-WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Moreau, P.; Stewart, A.K.; Dimopoulos, M.-A.; More

HemaSphere. 3(S1):260, June 2019.

S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3(S1):365, June 2019.

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Belch, A.; Bahlis, N.; White, D.; More

HemaSphere. 3(S1):962, June 2019.

Author:
Fadiloglu, E.

PS999 SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME

Hellesøy, M.; Fagerholt, O.H. E.; Tislevoll, B.S.; More

HemaSphere. 3(S1):449-450, June 2019.

S835 MASS CYTOMETRY REVEAL EARLY SIGNALING RESPONSES TO INDUCTION THERAPY IN IMMUNOPHENOTYPICALLY DEFINED LEUKEMIC CELL SUBSETS THAT PREDICT SURVIVAL IN AML

Tislevoll, B.S.; Fagerholt, O.H.E.; Hellesøy, M.; More

HemaSphere. 3(S1):371-372, June 2019.

Author:
Fagerlie, S.
Author:
Fagnan, A.

S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA

Fagnan, A.; Riera Piqué Borràs, M.; Ignacimouttou, C.; More

HemaSphere. 3(S1):8-9, June 2019.

Author:
Faict, S.
Author:
Faille, D.

PS1495 FUNCTIONAL ASSAYS USING WASHED PLATELETS FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: A RETROSPECTIVE STUDY COMPARING HEPARIN- INDUCED PLATELET ACTIVATION TEST VERSUS 14C-SEROTONIN RELEASE ASSAY

Gkalea, V.; Gonthier, M.-C.; Gendron, N.; More

HemaSphere. 3(S1):689, June 2019.

Author:
Faiman, B.
Author:
Fajgenbaum, D.

PS1403 IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS

Hoffmann, C.; Terriou, L.; Zinzani, P.L.; More

HemaSphere. 3(S1):644, June 2019.

Author:
Fakhfakh, Y.
Author:
Falanga, A.

PF802 ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L

Napolitano, M.; avvisati, G.; Carpenedo, M.; More

HemaSphere. 3(S1):353-354, June 2019.

S1646 THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY

Schieppati, F.; Russo, L.; Marchetti, M.; More

HemaSphere. 3(S1):761-762, June 2019.

Author:
Falantes, J.

PF757 REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3(S1):332-333, June 2019.

Author:
Falantes, J.F.

PF216 ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J.M.; More

HemaSphere. 3(S1):59, June 2019.

Author:
Falay, M.
Author:
Falco, P.

PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3(S1):244, June 2019.

Author:
Falcone, A.P.

PF644 CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)

Mele, A.; Prete, E.; De Risi, C.; More

HemaSphere. 3(S1):275-276, June 2019.

S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3(S1):396-397, June 2019.

Author:
Falcone, M. A.

PB2130 REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA

Mele, G.; Pastore, D.; Di Renzo, N.; More

HemaSphere. 3(S1):959, June 2019.

Author:
Falcone, U.
Author:
Falcucci, P.

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3(S1):3, June 2019.

Author:
Falini, B.

S104 THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3(S1):3, June 2019.

PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3(S1):65-66, June 2019.

Author:
Falkenburg, F.

PF761 REDUCED INTENSITY CONDITIONING REGIMEN WITH ALEMTUZUMAB BASED T CELL DEPLETION ENABLES EARLY POST-TRANSPLANTATION CELLULAR INTERVENTION RESTORING GRAFT VERSUS LEUKEMIA EFFECTS IN OLDER AML PATIENTS

Koster, E.; von dem Borne, P.; Bogers, L.; More

HemaSphere. 3(S1):334-335, June 2019.

Author:
Falleh, S.
Author:
Fan, A.
Author:
Fan, B.

PS1025 IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Roboz, G.J.; DiNardo, C.D.; Stein, E.M.; More

HemaSphere. 3(S1):461-462, June 2019.

PS1337 IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

Foran, J.M.; DiNardo, C.D.; Watts, J.M.; More

HemaSphere. 3(S1):610-611, June 2019.

Author:
Fan, H.

PF600 IGH TRANSLOCATIONS WITH UNDEFINED PARTNERS ARE ASSOCIATED WITH SUPERIOR OUTCOME IN MULTIPLE MYELOMA PATIENTS

Mao, X.-H.; An, G.; Xu, Y.; More

HemaSphere. 3(S1):253-254, June 2019.

Author:
Fan, L.
Author:
Fan, Y.
Author:
Fan, Z.
Author:
Fanale, M.

PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere.